TIDMFIPP

Frontier IP Group plc

08 September 2021

Reach - a non-regulatory announcement

AIM: FIPP

08 September 2021

Frontier IP Group Plc

("Frontier IP" or the "Group")

Portfolio news - Exscientia enters $70M collaboration to develop anti-viral therapeutics against Coronavirus and other viruses with pandemic potential

Frontier IP, a specialist in commercialising intellectual property, notes today's announcement below from portfolio company Exscientia concerning a $70 million collaboration with the Bill & Melinda Gates Foundation to develop anti-viral therapeutics against Coronavirus and other viruses with pandemic potential.

Exscientia statement begins:

Exscientia enters $70M collaboration to develop anti-viral therapeutics against Coronavirus and other viruses with pandemic potential

-- Four-year agreement with Bill & Melinda Gates Foundation to discover and develop small molecule therapeutics with less susceptibility to variants and greater patient access than current approaches

-- Exscientia to use leading AI platform and in-house drug expertise to discover and develop five phase 1-ready assets; Gates Foundation to contribute sector expertise in antivirals and global public health

   --      Investment accelerates Exscientia's Mpro Coronavirus small molecule therapeutics project 

Exscientia, an AI-driven pharmatech company with a mission to radically improve how drugs are discovered, today announced a four-year collaboration with the Bill & Melinda Gates Foundation, a non-profit focused on fighting global poverty, disease, and inequity, to develop small molecule therapeutics that tackle the current Coronavirus pandemic and help prepare for future pandemics. The collaboration will initially focus on developing broad-spectrum Coronavirus agents (e.g., SARS-CoV-2 and its variants, MERS), including accelerating Exscientia's lead program, which targets the main protease (Mpro) of SARS-CoV-2, the virus responsible for COVID-19. Subsequently, the collaboration will expand to develop therapeutics for influenza and Paramyxoviridae (e.g., Nipah), with the potential to develop additional programs as identified by the joint team.

Exscientia's AI-driven platform enables scientific concepts to be rapidly translated into precision-designed therapeutic candidates, with a goal of increasing probability of success and an accelerated path to the patient.

"The ongoing COVID-19 pandemic underscores the urgency to develop safe and effective broad-spectrum drugs to expand our armoury against viruses and their variants. We need to fight today's pandemic but also ensure we are prepared with new drugs to combat viruses with future pandemic potential. We are honoured to work alongside the Bill & Melinda Gates Foundation to advance this mission by ensuring accessibility and affordability of these therapeutics globally," commented Andrew Hopkins, Chief Executive Officer of Exscientia. "We believe that our AI-driven platform can accelerate the creation of better, more effective therapeutics that can address some of the world's most critical and emerging health risks."

"Small molecule therapeutics could provide a superior approach to guard global health," said Denise Barrault, Director of Portfolio Management at Exscientia. "Certain targets are prevalent across families of viruses, meaning that potent therapeutics could be broadly effective across multiple virus families. Further, this collaboration will focus on evaluating protein targets that are evolutionarily conserved and are less likely to develop resistance."

The Gates Foundation's program-related investment in Exscientia was made through its Strategic Investment Fund (SIF), a team that uses a suite of financial tools to address market failures and incentivise private enterprise to develop affordable and accessible products and services for low-income populations. SIF investments are intended to further the Gates Foundation's programmatic goals, not to generate financial returns. If any profit is generated by an investment, it will be used solely for charitable purposes through Gates Foundation philanthropic programs.

Under the terms of the agreement, Exscientia will receive a $35 million equity investment from the SIF, with the potential for additional grant funding to help advance development candidates through commercialisation. The Gates Foundation's program-related investment is subject to certain closing conditions being satisfied. As a global leader in pandemic preparedness, the Gates Foundation will also contribute its extensive expertise in funding the design, development, and distribution of antiviral drugs. Exscientia will lead the initial antiviral projects and apply its platform technology to research, discover, and develop up to five Phase 1-ready small molecule therapeutics for future pandemic preparedness. Exscientia will provide $35 million in matching contributions, through operations and funding for third party activities. Exscientia maintains worldwide rights to all developed products with a commitment to make the anti-viral products affordable and accessible to people in developing countries.

In July, Exscientia received a grant from the Gates Foundation to expedite the optimization of a new class of COVID-19 therapeutics created using its AI drug design platform, focused on a novel class of inhibitors targeting the SARS-CoV-2's main protease enzyme, Mpro, the causative agent of COVID-19. This work will continue under the collaboration announced today. Additionally, in 2020, the foundation awarded a $4.2 million grant to Exscientia to identify new innovative treatments for malaria and tuberculosis - two of the world's leading infectious disease killers - as well as new medicines for non-hormonal contraception.

Exscientia statement ends

ENQUIRIES

 
 Frontier IP Group Plc                         T: 020 7332 2338 
 Neil Crabb, Chief Executive                   neil@frontierip.co.uk 
  Andrew Johnson, Communications & Investor     M: 07464 546 025 
  Relations 
  andrew.johnson@frontierip.co.uk 
  Company website: www.frontierip.co.uk 
 Allenby Capital Limited (Nominated Adviser)   T: 0203 328 5656 
  Nick Athanas / George Payne 
 
  Exscientia 
  Amanda Galgay                                 media@exscientia.ai 
 
  Edelman Public Relations 
  Edelman PR (UK) 
  Nathan Field                                  T: + 44(0) 7866 411 
                                                198 
                                                nathan.field@edelman.com 
  Edelman PR (US) 
  Amanda Lazaro 
                                                amanda.lazaro@edelman.com 
 

ABoUT EXscientia

Exscientia is an AI-driven pharmatech company committed to discovering, designing, and developing the best possible drugs in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drug candidates are created. Exscientia's AI platform has now designed three drugs that are in Phase 1 human clinical trials.

Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia's AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.

Exscientia has offices in Oxford, Vienna, Dundee, Miami and Osaka. For more information visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain.

Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRASSSFEAEFSEEU

(END) Dow Jones Newswires

September 08, 2021 08:24 ET (12:24 GMT)

Frontier Ip (LSE:FIPP)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024 Haga Click aquí para más Gráficas Frontier Ip.
Frontier Ip (LSE:FIPP)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024 Haga Click aquí para más Gráficas Frontier Ip.